Back to search results

ALN-AGT01 RVR for Mild to Moderate Hypertension

This study is looking at a new treatment called ALN-AGT01 RVR for adults with mild to moderate high blood pressure (hypertension). You would first receive zilebesiran, another medication, before getting either ALN-AGT01 RVR or a placebo (an inactive substance). Researchers want to see how well ALN-AGT01 RVR works to lower blood pressure and how safe it is. They will measure changes in a substance in your blood called AGT and your seated office systolic blood pressure (the top number in a blood pressure reading). You could be eligible if you are between 18 and 75 years old and have specific blood pressure readings. The current recruitment status is unclear.

Study design
This interventional study plans to enroll 93 participants and has two parts, both involving single doses of the study medications.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Blood pressure will be measured up to Day 7 after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07553442

A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran

Recruiting
PHASE2Ages 18–75InterventionalTreatment
Alnylam Pharmaceuticals
~93 participants
Updated 2026-08-14 on ClinicalTrials.gov
What's tested:ALN-AGT01 RVRPlaceboZilebesiran

At a glance

Recruiting sites
1 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Part A: Percentage recovery from baseline in serum AGT
Measured over Up to Day 4
+1 more outcome measured

Conditions

Hypertension

Explore related trials

Hypertension

Where it's being run

3 sites across 3 states
California1
Florida1
Georgia1

Study leadership

  • Medical Director · STUDY_DIRECTOR · Alnylam Pharmaceuticals

Who to contact

Alnylam Clinical Trial Information Line
[email protected]
1-877-ALNYLAM
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Is an adult participant with a mean seated office systolic blood pressure (SBP) of at least 130 mmHg and no more than than 170 mmHg
Either not taking antihypertensive medication or on stable therapy with up to 2 antihypertensive medications
Is an adult participant with a mean seated office SBP of at least 140 mmHg and no more than 170 mmHg
Has discontinued all prior antihypertensive medication other than a calcium channel blocker (CCB) and/or thiazide/thiazide-like diuretic (if taking) for at least 3 weeks

Exclusion

Has known secondary hypertension or serum potassium more than 5 mmol/L
Has an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73m\^2

What this trial measures

  • Part A: Percentage recovery from baseline in serum AGTUp to Day 4
  • Part B: Percentage recovery from baseline in mean seated office SBPAt Day 4 and Day 7